Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
26.99
-1.63 (-5.70%)
At close: Apr 28, 2026, 4:00 PM EDT
27.39
+0.40 (1.48%)
After-hours: Apr 28, 2026, 6:49 PM EDT
Immunovant Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Immunovant stock have an average target of 31.22, with a low estimate of 17 and a high estimate of 50. The average target predicts an increase of 15.67% from the current stock price of 26.99.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Immunovant stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 4 | 5 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $29 → $32 | Hold | Maintains | $29 → $32 | +18.56% | Apr 15, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +29.68% | Feb 10, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $41 → $44 | Strong Buy | Maintains | $41 → $44 | +63.02% | Feb 9, 2026 |
| Truist Securities | Truist Securities | Hold Maintains $16 → $22 | Hold | Maintains | $16 → $22 | -18.49% | Jan 8, 2026 |
| Wolfe Research | Wolfe Research | Hold → Buy Upgrades $50 | Hold → Buy | Upgrades | $50 | +85.25% | Jan 6, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.01M
EPS This Year
-2.68
from -2.73
EPS Next Year
-2.68
from -2.68
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 90.7M | ||||||
| Avg | n/a | 8.0M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.64 | -2.31 | ||||||
| Avg | -2.68 | -2.68 | ||||||
| Low | -2.70 | -3.29 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.